Meta description: Boston Scientific acquires Valencia Technologies to add implantable tibial nerve stimulation to its urology portfolio, positioning for competitive growth in pelvic health devices.
Boston Scientific has agreed to acquire Valencia Technologies, a strategic move aimed at strengthening its urology and pelvic health portfolio by adding implantable tibial nerve stimulation technology. This transaction is part of a broader expansion in neuromodulation-based treatments. Investors and industry players should note the competitive implications in the urology device market as Boston moves closer to Medtronic’s position with its Altaviva system.
What are the deal terms?
Boston Scientific has not disclosed the financial terms of the acquisition. The transaction is expected to close in the first half of 2026. Valencia Technologies’ primary product, the eCoin device, received FDA clearance in 2022 for treating urge urinary incontinence. In its pivotal clinical trial, over two-thirds of patients achieved at least a 50% reduction in episodes.
The deal positions Boston Scientific to compete directly with Medtronic’s Altaviva, which entered the US market in late 2025. The competitive angle is important for shareholders, as Boston seeks to sustain high growth rates in its urology segment.
Why does this matter for strategic growth?
Boston Scientific’s strategy has centered on building a diversified portfolio of pelvic health solutions. The eCoin system adds implantable tibial nerve stimulation to its offerings, complementing sacral neuromodulation therapies acquired in the $3.3 billion Axonics deal in 2024. Company leadership views the ITNS segment as a high-growth adjacency to its established pelvic health product lines.
Revenue data indicates momentum. Boston’s urology segment generated $682 million in Q3 2025, marking a year-over-year increase of more than 28%. The addition of eCoin could sustain or accelerate this growth by broadening the clinical options available to physicians and patients.
How does this align with market trends?
The neurology device market is projected to exceed $25 billion in global valuation by 2034, according to industry analysis. Within urology, urge urinary incontinence affects tens of millions of adults in the US alone, creating a large addressable market for advanced neuromodulation treatments.
Boston Scientific has pursued acquisitions to expand beyond traditional device categories. In October 2025, it acquired Nalu Medical for around $533 million, adding peripheral nerve stimulation systems for chronic pain. Combined, these moves underline a deliberate strategy to diversify into multiple neuromodulation niches.
FAQ
1. When will the Valencia Technologies acquisition close?
The deal is expected to close in the first half of 2026.
2. What is the eCoin device?
It is an implantable tibial nerve stimulation system designed for urge urinary incontinence patients who have limited success with conservative treatments.
3. How did Boston’s urology segment perform recently?
In Q3 2025, the segment posted $682 million revenue, up over 28% from the same quarter in 2024.
4. Is this Boston Scientific’s first neuromodulation-related acquisition?
No. The company acquired Axonics in 2024 and Nalu Medical in 2025, both in neuromodulation-related fields.
Conclusion
Boston Scientific’s acquisition of Valencia Technologies marks another clear step in its bid to lead in pelvic health devices and broader neuromodulation markets. For founders and investors, the deal highlights how established medtech players are using acquisitions to secure competitive positions in high-growth therapeutic categories.
Disclaimer
This content is for informational purposes only and should not be considered financial advice.